BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 10, 2014
View Archived Issues
PD-404182 evaluated as an anti-HIV and anti-HSV microbicidal candidate
Read More
Autifony Therapeutics awarded grant to support phase IIa study of AUT-00063 for tinnitus
Read More
Novel XIAP inhibitors developed by Bristol-Myers Squibb and Ensemble Therapeutics
Read More
Nerviano Medical Sciences prepares new RET inhibitors
Read More
Pfizer presents novel dopamine D1 receptor agonists
Read More
OMP-59R5 plus etoposide is well tolerated in SCLC patients
Read More
PENELOPE data: pertuzumab + topotecan + paclitaxel in ovarian cancer
Read More
First-in-human results for anti-IGF-I/II antibody BI-836845
Read More
COMBI-d: first phase III trial of dabrafenib + trametinib in metastatic melanoma
Read More
Researchers patent novel tuberculosis vaccines
Read More
LG Life Sciences discloses new GPR40 agonists
Read More
Novel agents for HIV infection disclosed by Belgian team
Read More
Complexa completes series B financing to support development of CXA-10
Read More
KineMed and Pfizer extend research collaboration
Read More
Phase II study of fruquintinib initiated in non-small cell lung cancer
Read More
Ventana Medical Systems and MedImmune collaborate on PD-L1 assay
Read More
Critical Outcome Technologies completes financing round to support lead candidate
Read More
Curis re-initiates patient dosing in monotherapy trial of CUDC-427
Read More
National Institute of Mental Health recruits participants in study of radioligand [11C]ER-176
Read More
Immune Design confirms first patient treated in phase I clinical trial of LV-305
Read More
Agalimmune receives milestone payment triggered by phase I trials of Alphaject technology
Read More
Revive Therapeutics submits pre-IND package to the FDA for REV-002
Read More
FDA grants fast track designation to Epidiolex for Dravet syndrome
Read More
Pradaxa approved in E.U. for prevention of deep vein thrombosis and pulmonary embolism
Read More
Valeant's Jublia approved in U.S. for onychomycosis
Read More
FDA approves Eloctate for hemophilia A
Read More
Merck & Co. set to acquire Idenix Pharmaceuticals
Read More